Training family members and carers of opiate users in overdose management and naloxone administratio

Not Applicable

Completed

• Conditions: Opioid overdose; Mental and Behavioural Disorders; Mental and behavioural disorders due to use of opioids

• Registration Number: ISRCTN76786302
• Lead Sponsor: Institute of Psychiatry, Kings College London (UK)

Brief Summary

2014 results in https://pubmed.ncbi.nlm.nih.gov/24103087/ (added 07/08/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-05-05
• Study Completion: 2011-10-09
• Last Update Posted: 17 August 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 187

Inclusion Criteria

1. Aged 18 years or older, either sex
2. To have at least one family member (e.g., parent, partner, sibling, carer) who uses opioids
3. Opioid being the main drug type taken by their relative
4. To have sufficient knowledge of English to understand the study protocol, intervention and the research instruments

Exclusion Criteria

1. Not having close contact with the opioid user (e.g., if they do not live in same house or frequently visiting)
2. Already trained in overdose management and naloxone administration in the past 3 years
3. Not interested in taking part in the study
4. Not willing to accept randomisation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Measured at 6 and 12 months:<br> 1. Scores on the Overdose Knowledge Scale (OD-KS): risk, signs, action and naloxone domains and totals score<br> 2. Scores on the Overdose Attitudes Scale (OD-AS): competence, concerns and readiness domains and total score<br>

Secondary Outcome Measures

Name	Time	Method
<br> Measured at 6 and 12 months:<br> 1. Characteristics of the sample<br> 2. Number of family members who requested and successfully obtained a naloxone supply after interventions<br> 3. Number of family members who witnessed, experienced and managed an overdose at 3, 6 and 12 months after the intervention<br> 4. Preferable route and device of naloxone administration stated by family members<br> 5. Trainers' and trainees' feedback on the group-based training<br> 6. Scores in the Symptom Rating Test<br>